🫀 Semaglutide in HFpEF: Benefits Consistent Across Ages

🔥 Main in 3 points

• Semaglutide (2.4 mg weekly) improved symptoms, physical function (KCCQ-CSS, 6MWD), and reduced body weight in HFpEF, across all age groups (<55, 55–64, 65–74, ≥75 years).
• Benefits on dual primary and key secondary outcomes showed no significant interaction by age; safety profile did not differ across ages.
• Supports use of semaglutide in obese HFpEF patients regardless of age for improving quality of life and weight.

🧪 Context

Pooled pre-specified subanalysis from the STEP-HFpEF/STEP-HFpEF DM RCTs (n=1145) in patients with obesity-related HFpEF. Comparisons made across four age groups for efficacy and safety endpoints at 52 weeks.

📍 Practical significance

When selecting semaglutide for obese HFpEF, age need not restrict use—expect improved function and weight loss even in older adults.

🔗 Source

PubMed

DOI

🫀 Semaglutide in CKD—Cardiorenal Benefit in Diabetes and Non-Diabetes

🧾 Situation — Patients with CKD (T2DM or not), including those with eGFR <60.

✅ Do

• Consider semaglutide to reduce composite kidney events (RR 0.79) and cardiovascular mortality (RR 0.74).
• Expect significant reduction in MACE (RR 0.78); effect consistent across included subgroups.

⚠️ With caution

• Clinical data in non-diabetes CKD remains limited—monitor for emerging data.

🚫 Avoid

• Initiating without evidence-based indication for major kidney benefit in non-diabetics until further data.

🔗 Source

PubMed

DOI

🫀 Semaglutide and MASH: High-Dose + Long Duration Give Maximum Liver Benefit

🔥 Main in 3 points

• Semaglutide nearly doubles resolution rates for MASH (RR 1.98) and reduces steatosis, ELF score, and liver enzymes.
• No conclusive effect on fibrosis regression (RR 1.18; CI crosses 1).
• All-cause and CV mortality risk are also reduced (RR 0.82/0.83).

🧪 Context

Meta-analysis of 22 RCTs, 32,013 patients with or at risk of metabolic steatohepatitis (MASH); subgroup analysis shows best benefit at ≥2.0 mg/week and ≥12 months.

📍 Practical significance

Use higher-dose, sustained semaglutide for best liver and metabolic outcomes in MASH, but set expectations regarding fibrosis improvement.

🔗 Source

PubMed

DOI

⚠️ Semaglutide: Mortality Benefit but Higher GI AEs in High CV Risk

🧪 Context

Systematic review/meta-analysis and Trial Sequential Analysis of 50 RCTs (n=54,972, diverse high CV risk; 38% T2DM).

📊 Numbers

• Reduces all-cause mortality (RR 0.85), MI (RR 0.77), and SAEs (RR 0.93).
• Raises non-serious GI AE risk: nausea (RR 3.00), vomiting (RR 4.12), diarrhea (RR 1.88).

📍 Actions

• Counsel all CV risk patients on GI side effects before initiation.
• Titrate cautiously, preemptively discuss GI symptom management, but expect overall lower mortality/MI risk.

🔗 Source

PubMed

DOI

🫀 Semaglutide in Adolescents with Obesity: STEP TEENS Subanalysis

🧪 What was studied

Secondary analysis of STEP TEENS RCT on semaglutide (2.4 mg weekly) versus placebo in obese adolescents (n=193), over 68 weeks.

📈 Key results

Semaglutide reduced fasting insulin (-33.6% vs -10.1%), HOMA-IR (-35% vs -5.3%), HbA1c, ALT, triglycerides, LDL, and total cholesterol more than placebo. Improvements were greater in those with ≥20% BMI reduction.

📍 What this changes in practice

Semaglutide not only reduces weight in adolescent obesity but also provides metabolic/cardiometabolic benefit—important in treatment selection for severe cases.

🔗 Source

PubMed

DOI

🩸 Mediation of Semaglutide CV Benefit: HbA1c Is the Main Driver

❓ Practice question

Which factors most mediate reduction in major CV events (MACE) with semaglutide/liraglutide?

✅ Study answer

Causal mediation analysis (LEADER/SUSTAIN-6): For semaglutide, 51.8% of 3P-MACE risk reduction mediated by HbA1c lowering, with less contribution from UACR (12.4%) and SBP (6.7%). Effects stable across vulnerable subgroups (CKD, CVD).

📍 How to apply

Prioritise HbA1c reduction for maximizing CV benefit with semaglutide. Monitor albuminuria and SBP, but these play smaller roles in mediation.

🔗 Source

PubMed

DOI

⚠️ Ocular Inflammation and Optic Disc Edema on Semaglutide

🧪 Context

Case reports: optic disc edema in 2 T2DM patients (multicenter RCT), inflammatory optic neuritis/scleritis in 1 (post-marketing). All presented weeks to months after semaglutide initiation; resolved with corticosteroids.

📊 Numbers

Retinopathy at baseline excluded. Visual acuity generally preserved; fundoscopic/OCT confirmed disc edema. No lasting optic nerve loss.

📍 Actions

Vigilant ophthalmic monitoring, especially within first 6 months of semaglutide. Don’t dismiss new visual symptoms as non-arteritic ischemic optic neuropathy alone—consider corticosteroid-responsive inflammation.

🔗 Source

Edema Case DOI

Neuritis Case DOI

🧾 Oral Semaglutide as Add-on to SGLT2i in Uncontrolled T2DM

✅ Do

• Add oral semaglutide in patients poorly controlled on SGLT2i; real-world study (n=142) shows significant HbA1c, weight, BMI, and lipid reductions at 6–9 months.
• 39.6% achieved HbA1c ≤7%; nearly 19% saw both ≥1% HbA1c drop and ≥5% weight loss.

⚠️ With caution

• Most AEs were mild GI symptoms; low risk of hypoglycaemia, but monitor on initiation.

🚫 Avoid

• Relying solely on SGLT2i if glycemic targets unmet—consider adding semaglutide.

🔗 Source

PubMed

DOI

⚠️ Semaglutide and Pregnancy—No Consistent Major Birth Defect Signal

🧪 Context

Systematic review—5 studies, 1128 pregnancies exposed to semaglutide before or during gestation.

📊 Numbers

Spontaneous abortion rates (~23%) comparable to diabetes/obesity controls; congenital malformations 8.3% (vs insulin, no significant risk increase). Reports of macrosomia or hypoglycemia after stopping semaglutide; some preterm/LGA infants, not birth defects.

📍 Actions

No clear birth defect excess, but data sparse and heterogeneous: avoid semaglutide in pregnancy; if exposure occurs, close fetal monitoring/women's health referral.

🔗 Source

PubMed

DOI

🧑‍⚕️ Real-World Data: Oral Semaglutide Delivers A1c, Weight, and Satisfaction Gains

🧪 What was studied

Prospective multicentre study of 192 Saudi adults with T2DM initiated on daily oral semaglutide, 34–44 week follow up.

📈 Key results

• Mean A1c drop: -1.0%
• Mean weight loss: -4.4 kg
• 61.9% hit A1c <7%
• ~22% achieved ≥1% A1c drop + ≥3% weight loss
• Treatment satisfaction improved, safety favorable

📍 What this changes in practice

Daily oral semaglutide is effective for T2DM not on injectables—can expect robust metabolic and satisfaction gains in diverse real-world populations.

🔗 Source

PubMed

DOI